This study was funded by the American Cancer Society (grant TURSG-02-081), the California Breast Cancer Research Program (grant 7PB-0070), and the National Cancer Institute (grant 1R01CA119197-01A1). Financial disclosure None of the authors has any financial disclosures. ""Objective: An American Psychosocial Oncology Society workgroup has developed indicators of the quality of psychosocial care that can be measured through review of medical records. The present report describes the first large-scale use of these indicators to evaluate psychosocial care in outpatient medical oncology settings. Methods: Medical records of 1660 colorectal, breast and non-small cell cancer patients first seen by a medical oncologist in 2006 at 11 practice sites in Florida were reviewed for performance on indicators of the quality of psychosocial care. Results: Enzalutamide concentration
Assessment of emotional well-being was significantly less likely to be documented than PD-1 inhibitor
assessment of pain (52 vs 87%, p<0.001). A problem with emotional well-being was documented in 13% of records and evidence of action taken was documented in 58% of these records. Ten of eleven practice sites performed below an 85% threshold on each indicator of psychosocial care. Variability in assessment of emotional-well being was associated (p<0.02) with practice site and patient gender and age while variability in assessment of pain was associated (p<0.001) with practice site and cancer type. Conclusions: Findings illustrate how use of the psychosocial care indicators permits identification <a href="http://www.selleckchem.com/products/gsk1120212-jtp-74057.html
">click here of specific practice sites and processes of care that should be targeted for quality improvement efforts. Additionally, findings demonstrate the extent to which routine assessment of emotional well-being lags behind routine assessment of pain in cancer patients. Copyright ? 2010 John Wiley & Sons, Ltd. ""To understand factors influencing the process of adjustment to a diagnosis of glioma. Twenty-six patients and 23 relatives took part in 80 in-depth qualitative interviews conducted at five key stages: before formal diagnosis, at start of treatment, on completion of treatment, 6?months post treatment, and post bereavement. High levels of distress were reported, particularly preceding and following diagnosis. Many participants described lack of specific information in the early part of their illness and a lack of clarity about what was wrong and what was going to happen next. They often desired more procedural information, as well as information about their condition and treatments available, although there was variation in the timing of when people were ready to hear this. Receiving reassurance and support was essential to patients and their relatives to help them come to terms with their illness.